Financial Performance - The company reported a total revenue of 1.2 billion RMB for the fiscal year 2022, representing a year-over-year increase of 15%[5]. - The company has set a revenue guidance of 1.5 billion RMB for the fiscal year 2023, projecting a growth of 25%[5]. - The company's total revenue for the fourth quarter reached CNY 1,064,700,359.52, showing a significant increase compared to previous quarters[31]. - The company reported a total net asset of CNY 2,961,058,106.3, a slight decrease of 1.40% compared to the previous period[29]. - The company reported a total revenue of 387.83 million yuan in 2022, representing a year-on-year growth of 1.19%[104]. - The company's operating profit and net profit attributable to shareholders were 50.45 million yuan and 16.08 million yuan, respectively, both showing a decline compared to the previous year due to macroeconomic challenges[104]. - The women's apparel segment achieved a revenue of 153.49 million, a decrease of 9.27% compared to 2021's 169.15 million[122]. - The company faced a 99.40% drop in net profit after deducting non-recurring gains and losses, amounting to CNY 1.11 million[52]. - The net cash flow from operating activities decreased by 53.70% to CNY 235.67 million in 2022[52]. - Basic earnings per share fell by 90.74% to CNY 0.0363, reflecting significant profitability challenges[52]. User Growth and Market Expansion - User data indicates a growth in active users by 25%, reaching 3 million by the end of 2022[5]. - The company is expanding its market presence in Southeast Asia, targeting a 20% market share by 2025[5]. - The company is actively expanding its network of subsidiaries in the medical beauty industry, with multiple holdings across various regions[22]. Product Development and Innovation - Research and development expenses increased by 10% to 150 million RMB, focusing on innovative textile technologies[5]. - The company has established high-end medical aesthetics brands "Milan Baiyu" and "Jingfu Medical Aesthetics" after investing in South Korean medical management institutions in 2016, and has expanded its portfolio through acquisitions[75]. - The company has implemented a dual-brand strategy for its high-end product lines, enhancing its brand positioning and market reach[80]. - The company has established a high-efficiency cross-functional product development management model to improve product accuracy and efficiency[121]. Strategic Acquisitions and Investments - The company plans to pursue strategic acquisitions to enhance its supply chain efficiency, with a budget of 200 million RMB allocated for this purpose[5]. - The company holds a 100% stake in Shaanxi Gao Yisheng Medical Beauty Hospital Co., Ltd., enhancing its market presence[22]. - The company has made acquisitions to consolidate its market position, including a 75% stake in Kunming Hancheng Medical Beauty Hospital[33]. - The company acquired a controlling stake in Kunming Hancheng Medical Beauty Hospital to enhance its medical beauty business and accelerate its national expansion[102]. Market Trends and Challenges - The apparel industry in China is under pressure due to weak domestic and international demand, high raw material costs, and a complex foreign trade environment[61]. - In 2022, the retail sales of clothing in China decreased by 7.7% year-on-year, totaling CNY 922.26 billion, with a significant decline of 14.2% in December alone[39]. - Major retail enterprises reported a year-on-year drop of 14.79% in clothing retail sales and 18.61% in retail volume for the entire year, with December figures showing declines of 34.32% in sales and 38.80% in volume[39]. - The non-surgical medical beauty market in China is expected to grow from 75.2 billion yuan in 2021 to 227.9 billion yuan by 2025, with a CAGR of 31.9%[95]. Online Sales and Digital Strategy - The company has seen a steady increase in online sales, with significant growth on traditional e-commerce platforms and a strong performance in live-streaming sales on Douyin[74]. - The total omni-channel payment amount exceeded 1.6 billion, representing a year-on-year growth of over 35%, with Tmall channel payments increasing by 22% and Douyin channel payments growing by over 80%[152]. - Online sales for women's apparel brands exceeded 500 million, representing a 52% year-over-year growth[121]. - The online sales accounted for 33.14% of total women's apparel revenue, amounting to 50,869.88 million, up from 19.77% in the previous year[157]. Financial Health and Cash Flow - Cash and cash equivalents decreased from 477,983,675.86 yuan (6.66%) at the beginning of the year to 430,591,128.25 yuan (6.06%) at year-end, a decrease of 0.60%[198]. - The inventory turnover days for women's clothing were 455 days, with inventory increasing by 19.62% due to demand shrinkage[181]. - Investment cash inflow dropped by 48.39% to 862,080,967.87 yuan, attributed to decreased trading amounts of financial products[193]. - The return on investment was 51,292,776.71 yuan, accounting for 120.40% of total profit, driven by gains from joint ventures and financial products[197].

Group 1: Investor Relations Activity - The investor relations activity was a strategic cooperation announcement between Akabong and Tmall, held on September 22, 2015 [2][3] - The event aimed to accelerate the entry of Akabong, a leading Korean baby and children's brand, into the domestic market [2][3] Group 2: Strategic Partnerships - Akabong will introduce 6 brands to Tmall, providing competitive seasonal products and exclusive online offerings [3][4] - The partnership with Guangzhou Ruoyuchen Technology Co., Ltd. is crucial for the online and offline strategic layout of Akabong in China [3][4] Group 3: Company Holdings and Strategy - Langzi Holdings owns 20% of Ruoyuchen, which is a leading e-commerce marketing and operation service provider in China [4] - The company is focused on building a "pan-fashion ecosystem" through investments in Akabong, Ruoyuchen, and other brands, despite recent capital market fluctuations [4][5] Group 4: Multi-Brand Operations - Langzi currently operates several mid-to-high-end women's clothing brands, including Lancy, Mojo S.PHINE, and others, covering various age groups and market segments [5] - The company plans to continue expanding its brand portfolio while strengthening existing brands, with further efforts expected in the second half of 2015 [5]

Group 1: Company Strategy and Performance - The company has acquired the infant brand "Akaban," enhancing product planning and internal management, leading to improved operational efficiency and a projected breakeven for the year, reversing previous losses before the acquisition [2][3] - The company's associate, Guangzhou Ruoyu Technology Co., Ltd., was listed on the New Third Board on December 2, with the stock code 834647 [3] - The termination of the acquisition of Lianzhong International will not affect the advancement of the company's "Pan-Fashion Ecosystem" strategy, as the company continues to seek quality targets aligned with its strategic direction [3] Group 2: Market Interest and Opportunities - Recent inquiries from media and investment institutions indicate significant interest in the company's potential involvement in the cosmetic surgery industry [3] - The "Pan-Fashion Ecosystem" strategy aims to leverage the company's advantages in marketing channels, VIP management, IT information management systems, and connections with the Korean fashion industry to meet the diverse needs of mid-to-high-end female customers [3] - The formal approval of the China-South Korea Free Trade Agreement is expected to reduce import costs for certain materials and garments, enhancing operational efficiency [4]

Group 1: Economic Environment and Industry Impact - The current economic environment is significantly affecting the apparel industry, with expectations for improvement in 2015 [1] - The company aims to maintain stable growth by focusing on enhancing store sales levels while expanding its channels [1] Group 2: Strategic Development and Brand Positioning - The company's strategic adjustments are becoming clearer, with plans to develop three main centers: fashion women's wear, children's wear, and ethnic handicrafts [1] - The introduction of children's clothing and infant products is a core focus for the company [1] Group 3: Market Expansion and E-commerce - The company is leveraging its channel advantages to expand the market for traditional handicraft products from Tibet [2] - With the rapid development of e-commerce, the company is actively exploring suitable online sales channels, initially set up to manage inventory [2] Group 4: Supply Chain and Operational Efficiency - Participation in the program "The Goddess's New Clothes" has led to new requirements for improving the supply chain and logistics [2] - The company is gradually enhancing internal processes to improve efficiency and better connect raw materials with finished products [2]

证券代码：002612 证券简称：朗姿股份 朗姿股份有限公司投资者关系活动记录表 编号：2020-001 | --- | --- | --- | |------------------------------|-------------------------------------|------------------------------------------------------------| | | | | | 投 资 者 关 | ■ 特定对象调研 | □分析师会议 | | 系 活 动 类 | □ | 媒体采访 □业绩说明会 | | 别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参 与 单 位 | 国泰君安：刘越男、赵政 | | | 名 称 及 人 | 民生加银：蔡晓 | | | 员姓名 | 亚太财产：陈光 | | | 时间 | 2020 年 11 月 3 | 日上午 10:00 ； | | 地点 | 朗姿大厦 16 | 层会议室 | | | | | | 上 市 公 司 接 待 人 员 姓名 | 董事会秘书：王 ...

Group 1: Company Overview and Strategy - The company is focused on building a "pan-fashion industry interconnected ecosystem" to strengthen its position in the fashion women's wear sector and expand into medical beauty and children's products [4][5]. - The company aims to leverage the rise of new retail formats and innovate its business model to enhance competitiveness [4]. Group 2: Business Performance - In the first three quarters of 2020, the women's wear segment generated revenue of 860 million CNY, with a monthly narrowing decline [5]. - The online sales during the "Double 11" shopping festival reached 120 million CNY, representing a 89% increase compared to the previous year [5]. - The children's wear segment reported revenue of 353.83 million CNY in the first half of 2020, with a slight decline compared to the same period last year [6]. Group 3: Medical Beauty Segment - The medical beauty segment achieved revenue of 598.19 million CNY and a net profit of 46.99 million CNY in the first three quarters of 2020 [6][7]. - The company operates 18 medical beauty institutions, including 5 hospitals, with a focus on expanding in first- and second-tier cities [6][9]. - The medical beauty market in China is projected to grow from 224.5 billion CNY in 2018 to 315 billion CNY in 2020, with an annual growth rate exceeding 20% [8]. Group 4: Market Position and Future Outlook - The penetration rate of medical beauty services among women aged 18-40 in China is 7.4%, compared to 42% in South Korea, indicating significant growth potential [8]. - The company plans to expand its medical beauty business through both organic growth and acquisitions, focusing on core cities in central and western China in the short term [11]. - The company emphasizes the importance of quality and compliance in its medical beauty services to build consumer trust [10][12].

Financial Performance - The company's operating revenue for Q3 2022 was ¥855,055,322.73, a decrease of 0.73% compared to the same period last year[6]. - The net profit attributable to shareholders for Q3 2022 was ¥8,275,730.15, down 87.21% year-on-year[6]. - The net profit after deducting non-recurring gains and losses was ¥7,056,616.37, a decline of 89.25% compared to the previous year[6]. - Basic earnings per share for Q3 2022 were ¥0.0187, reflecting an 87.21% decrease year-on-year[6]. - Total operating revenue for the third quarter of 2022 was CNY 2,664,182,457.51, a slight increase from CNY 2,650,707,735.25 in the same period last year, representing a growth of approximately 0.51%[27]. - Net profit for the third quarter was CNY 24,476,518.94, a significant decrease from CNY 151,066,581.01 in the previous year, reflecting a decline of approximately 83.8%[29]. - Earnings per share (EPS) for the quarter was CNY 0.0396, down from CNY 0.3576 in the same quarter last year, indicating a decrease of about 88.9%[32]. - The total comprehensive income for the quarter was CNY 12,312,617.30, a decrease from CNY 131,188,157.50 in the previous year, indicating a decline of approximately 90.6%[31]. Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥6,881,965,605.32, representing a 0.46% increase from the end of the previous year[6]. - As of September 30, 2022, the total assets amounted to RMB 6.88 billion, with total liabilities of RMB 1.72 billion[21]. - Total liabilities increased to CNY 3,287,892,107.41 from CNY 3,231,949,582.30, showing a rise of approximately 1.74%[27]. - The company's total equity decreased to CNY 3,594,073,497.91 from CNY 3,618,801,780.49, a decline of about 0.69%[27]. Cash Flow - The cash inflow from operating activities totaled CNY 2,934,414,025.59, a decrease of 5.7% compared to CNY 3,111,132,217.54 in the previous period[36]. - The net cash flow from operating activities was CNY 179,722,537.15, down from CNY 377,669,779.50 in the previous period, indicating a decline of 52.4%[36]. - The cash outflow from investing activities was CNY 607,941,873.40, significantly lower than CNY 1,888,274,393.57 in the previous period, reflecting a decrease of 67.8%[36]. - The net cash flow from financing activities was negative at CNY -195,199,820.88, contrasting with a positive CNY 157,587,743.46 in the previous period[36]. - The total cash and cash equivalents at the end of the period stood at CNY 425,479,603.99, compared to CNY 286,221,453.70 at the end of the previous period, representing an increase of 48.7%[36]. Expenses - Total operating costs increased to CNY 2,666,217,159.79 from CNY 2,527,089,634.33, marking an increase of about 5.5% year-over-year[29]. - Research and development expenses for the quarter were CNY 84,305,069.55, compared to CNY 76,091,484.03 in the previous year, reflecting an increase of approximately 10.3%[29]. - Sales expenses rose to CNY 1,135,229,353.22 from CNY 1,026,385,864.76, indicating an increase of about 10.6% year-over-year[29]. - The cash outflow for employee payments was CNY 591,203,203.73, an increase of 8.3% from CNY 545,925,592.19 in the previous period[36]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 78,376, with the largest shareholder, Shen Dongri, holding 47.82% of shares[15]. - The company has a total of 2.13% shares held by the third phase employee stock ownership plan, indicating employee engagement in the company's growth[15]. Investments and Acquisitions - The company's cash acquisition of 75% equity in Kunming Hancheng Medical Beauty Hospital was valued at approximately RMB 158.11 million, based on an assessment report[19]. - The company plans to expand its market presence through the acquisition of Kunming Hancheng, enhancing its operational capabilities in the medical beauty sector[19]. Other Financial Metrics - Non-operating income included government subsidies of ¥789,837.97, with total non-recurring gains and losses amounting to ¥1,219,113.78 for the quarter[7]. - The company reported a significant increase in construction in progress, rising 183.66% to ¥72,842,281.79 due to renovations[11]. - Financial expenses increased by 36.29% to ¥61,390,898.59, primarily due to increased loan interest expenses[11]. - The company experienced an 88.18% decrease in trading financial assets, totaling ¥20,000,000.00, mainly due to the redemption of financial products[11]. - The company reported accounts receivable of RMB 244.33 million, a slight decrease from RMB 253.87 million in the previous period[23]. - Inventory increased significantly from RMB 1.03 billion to RMB 1.22 billion over the same period, indicating a growth of approximately 18.1%[23]. - The company's short-term borrowings rose from RMB 658.85 million to RMB 793.50 million, reflecting an increase of about 20.4%[23]. - The total non-current assets increased from RMB 4.70 billion to RMB 4.79 billion, showing a growth of approximately 1.8%[23].

Financial Performance - The company reported a revenue of 1.2 billion RMB for the first half of 2022, representing a year-on-year increase of 15%[1] - The company's operating revenue for the reporting period was approximately ¥1.81 billion, representing a 1.10% increase compared to the same period last year[25] - The company achieved a total operating revenue of 1,809.13 million yuan in the first half of 2022, representing a year-on-year increase of 1.10%[35] - The net profit attributable to shareholders of the listed company was approximately ¥9.25 million, a decrease of 90.09% year-on-year[25] - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥13.08 million, down 85.10% from the previous year[25] - The net cash flow from operating activities was approximately ¥107.07 million, a decline of 50.14% compared to the same period last year[25] - The total assets at the end of the reporting period were approximately ¥6.70 billion, a decrease of 2.26% from the end of the previous year[25] - The net assets attributable to shareholders of the listed company were approximately ¥2.94 billion, down 0.66% from the previous year[25] - The basic earnings per share were ¥0.0209, reflecting a 90.09% decrease year-on-year[25] - The diluted earnings per share were also ¥0.0209, showing a 90.09% decline compared to the same period last year[25] - The weighted average return on net assets was 0.31%, down 2.81% from the previous year[25] Market Expansion and Strategy - The company plans to expand its market presence by opening 30 new retail locations by the end of 2023[3] - The company is exploring potential acquisitions in the fashion industry to enhance its product offerings[7] - A strategic partnership with a leading technology firm aims to improve online sales channels, targeting a 25% increase in e-commerce revenue[8] - The company aims to innovate through product and service enhancements to create value for customers, maintaining a commitment to quality and brand reputation[35] - The company is focusing on expanding its medical beauty business through the growth of self-built hospital-level institutions and increasing the scale of its chain operations[71] - The company aims to enhance its domestic infant clothing market share by promoting the ETTOI brand and leveraging local designers[80] - The company is focusing on expanding cooperation with external investment institutions and industry funds to enhance its capital market presence[163] Product and Service Development - New product launches in the fashion segment contributed to a 10% increase in sales volume compared to the previous year[4] - The company has invested 200 million RMB in R&D for new technologies in medical beauty treatments[5] - The company has optimized its product development process using a self-developed PLM system, improving accuracy and efficiency in product design[55] - The company launched the "Seedling Doctor Training Program" in 2022 to systematically train qualified medical personnel through various educational methods[70] - The company has established three major medical beauty brands: Milan Baiyu, Jingfu Medical Beauty, and Gao Yisheng, each targeting different market segments[62][65][66] Operational Efficiency and Management - The company has optimized its organizational structure by establishing regional divisions to improve management efficiency and resource integration[70] - The company is enhancing management efficiency through refined management practices and increasing the proportion of online business to mitigate rising labor costs[156] - The company is leveraging shared resources among its medical beauty brands to enhance competitiveness and optimize procurement and marketing strategies[160] - The company is enhancing its operational efficiency and profitability through innovative business models and improved management capabilities, aiming to increase its financing credibility and bank credit scale[163] Customer Engagement and Sales Channels - The online sales channel for women's apparel reached nearly 200 million yuan, representing a year-on-year growth of approximately 20%[55] - The overall payment amount across all channels exceeded 650 million yuan, marking a 30% increase year-on-year, with Douyin channel payments soaring by 97%[56] - The company has established a marketing network with 603 offline sales terminals and 30 online channels for its women's clothing business[95] - The company has a loyal customer base, with over 319,300 offline VIP customers and approximately 349,000 online VIP customers in the women's clothing segment[95] Challenges and Risks - Risk management strategies have been outlined to address potential market fluctuations and operational challenges[10] - The company faces risks related to medical accidents and personnel turnover, with a focus on maintaining high standards in medical procedures and attracting talent through incentive policies[158] - The company is addressing rapid changes in consumer demand in the mid-to-high-end women's clothing market by improving design innovation and maintaining a multi-brand strategy[160] Financial Commitments and Governance - The company has committed to providing at least RMB 500 million to support its medical beauty business strategy within two years following the completion of a share reduction plan[196] - The controlling shareholders have pledged not to transfer more than 25% of their shares annually during their tenure[196] - The company has established strict principles for related party transactions to ensure fairness and compliance with legal regulations[196] - The company has committed to adhering to the latest regulatory opinions regarding the lock-up period and related party transactions[191] Social Responsibility and Compliance - The company’s subsidiary, Langzi Medical, was awarded the "2022 Outstanding Corporate Social Responsibility" for its commitment to social responsibility and public welfare initiatives[186] - The company has not been penalized for environmental issues during the reporting period and actively collaborates with suppliers to build a green supply chain[185]

朗姿股份有限公司 2022 年第一季度报告全文 证券代码：002612 证券简称：朗姿股份 公告编号：2022-027 朗姿股份有限公司 2022 年第一季度报告 2022 年 04 月 1 朗姿股份有限公司 2022 年第一季度报告全文 朗姿股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗 漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|-------------- ...

Dividend and Financial Performance - The company plans to distribute a cash dividend of 0.70 CNY per 10 shares to all shareholders based on a total share capital of 442,445,375 as of December 31, 2021[5]. - The company's operating revenue for 2021 was approximately ¥3.67 billion, representing a 27.42% increase compared to ¥2.88 billion in 2020[27]. - The net profit attributable to shareholders for 2021 was approximately ¥187.45 million, an increase of 31.97% from ¥142.04 million in 2020[27]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥184.16 million, reflecting an 82.00% increase from ¥101.19 million in 2020[27]. - The net cash flow from operating activities for the year 2021 was CNY 470,584,897.30, representing an increase of 24.07% compared to CNY 379,278,066.80 in 2020[28]. - Basic and diluted earnings per share for 2021 were CNY 0.4237, up 31.42% from CNY 0.3224 in 2020[28]. - The total assets at the end of 2021 reached CNY 6,850,751,362.79, a 32.93% increase from CNY 5,153,564,692.50 at the end of 2020[28]. Medical Beauty Segment - The company has a total of 100% ownership in several subsidiaries, including Sichuan Milan and Shenzhen Milan, which are part of its medical beauty segment[16]. - The company holds a 60% stake in Xi'an Milan, further expanding its presence in the medical beauty industry[16]. - The company has established a significant number of subsidiaries in the medical beauty sector, indicating a strong market expansion strategy[16]. - The company is focused on developing new products and technologies within its medical beauty division, aiming to enhance its market position[16]. - The medical beauty business has seen rapid growth, with a nationwide strategic expansion and improved operational management capabilities[44]. - The company operates 28 medical beauty institutions, including 5 comprehensive hospitals and 23 clinics, primarily located in major cities[68]. - Milan Baiyu, a high-end medical beauty brand, has served over 700,000 clients and has been recognized as one of the top ten medical beauty hospitals in Chengdu[69]. - The medical beauty segment achieved revenue of RMB 1,119.93 million, a year-on-year increase of 37.84%[76]. - Gross profit for the medical beauty segment was RMB 580.50 million, with a gross margin of 51.83%, down 2.50% year-on-year[76]. - Non-surgical medical beauty services accounted for 73.86% of the medical beauty revenue in 2021[112]. Women's Apparel Segment - The company operates in the mid-to-high-end women's clothing sector, which is experiencing a trend towards multi-brand operations and increased market concentration[39]. - The company emphasizes the importance of product quality, style, and consumer experience in the competitive landscape of the women's apparel market[40]. - The women's apparel segment achieved revenue of 1.691 billion CNY, a year-on-year increase of 27.86%[62]. - Gross profit for the women's apparel segment reached 1.033 billion CNY, with a gross margin of 61.08%, up 7.43% from the previous year[62]. - The online sales channel for women's apparel generated total revenue of 335 million CNY, representing a year-on-year growth of approximately 20%[66]. - The company operates seven proprietary women's clothing brands, focusing on differentiated product positioning and design styles to meet diverse consumer needs[45]. - The LɅNCY brand has undergone a brand upgrade, emphasizing women's individuality and empowerment through its new product lines[46]. - The company has established a multi-brand matrix to cater to the differentiated fashion demands of women across various age groups[41]. Market Trends and Strategies - The market for mid-to-high-end women's clothing is projected to grow, with retail sales expected to rise from 22.6% in 2018 to 23.4% by 2023[39]. - The company has outlined its future development plans, which include potential market expansion and strategic acquisitions[5]. - The company aims to expand its medical beauty services nationally, having established a strong presence in Southwest China[68]. - The company has implemented a three-tier operational management system to optimize management as the business expands[78]. - The company is focused on developing a standardized operational system across its medical beauty brands to ensure quality and safety[76]. - The company aims to leverage policies promoting new consumption and product innovation to drive high-quality development in the domestic clothing market[200]. Research and Development - The company has applied for 10 invention patents and 25 utility model patents in the medical beauty sector during the reporting period[101]. - The company has invested in R&D projects aimed at improving product quality and reducing production costs, including a new structure for decorative chains in clothing[151]. - The company's R&D investment increased by 20.84% to ¥112,549,448.81 in 2021, compared to ¥93,137,288.37 in 2020[159]. - The company has filed multiple patents in 2021, including a new optical treatment device and a breast lifting wire ruler, aimed at enhancing operational efficiency and patient comfort[157]. Financial Management and Investments - The company reported a significant increase in investment income, contributing 29.73% to total profit, primarily from joint venture investments and financial management gains[162]. - The total investment for the reporting period was ¥2.51 billion, a 32.72% increase compared to the previous year[169]. - The company has established several new subsidiaries during the reporting period, including Chengdu Jinjing Skin Medical Beauty Clinic, with no significant impact on overall operations and performance[194]. - The company has not encountered any issues or other situations regarding the use and disclosure of raised funds[186]. Market Outlook - The continuous growth of disposable income and the increase in high-net-worth individuals provide strong momentum for the development of the mid-to-high-end women's and children's clothing markets, as well as the medical beauty industry[198]. - The clothing industry is expected to experience a low-speed operational trend in 2022 due to a high base effect from 2021 and a more complex macroeconomic environment[200]. - Domestic clothing sales are projected to continue recovering, but the growth rate is expected to show marginal slowdown[200].